Avantor, Inc. is a global provider of mission-critical products and services to customers in the biopharma & healthcare, education & government, and advanced technologies & applied materials end markets. The company operates through two primary business segments: Laboratory Solutions and Bioscience Production. Its portfolio includes ultra-high purity chemicals, reagents, lab supplies, filtration systems, analytical instruments, and high-purity silicone materials for medical implants. Avantor serves customers through its VWR distribution channel, which offers millions of SKUs from third-party suppliers and private label products, and through proprietary manufacturing capabilities. Key brands include J.T. Baker for high-purity chemicals, Masterflex for fluid handling systems, and NuSil for medical-grade silicones. The company serves customer locations across the Americas, Europe, and the AMEA region. Avantor was incorporated in 2017 following the acquisition of VWR, with its legacy tracing back to the founding of J.T. Baker Chemical Company in 1904. The company provides value-added services including procurement, logistics, inventory management, and biopharmaceutical material scale-up support.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Industrial Distribution Homepage avantorsciences.com
Sector Industrials IR page ir.avantorsciences.com/overview/default.aspx
Tags
life sciences, biopharmaceutical, laboratory supplies, high-purity chemicals, medical devices, fluid handling, silicone materials, scientific research, analytical instruments, distribution, VWR, J.T. Baker, Masterflex, NuSil, Avantor Business System, Inventory Manager
Press page —

Metrics

Valuation  
Market cap $ 10.198B
Market cap (USD) $ 10.198B
P/E 30.10
PEG —
P/BV 1.75
P/S 1.54
P/OCF 17.44
P/FCF 23.22
Dividend yield —
Turnover / mcap —
Returns  
ROE -9.2%
ROI -5.6%
ROIC -1.9%
Profit margin -8.1%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 63.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 16
Quality score -52.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 6.552B 6.784B 6.967B 7.512B 7.386B 6.394B 6.04B 5.864B
Net profit -530.2M 711.5M 321.1M 686.5M 572.6M 116.6M 37.8M -86.9M
Free cash flow 495M 692M 723.6M 710.2M 842.5M 868.2M 302.4M 162.8M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 11.46 21.07 22.83 21.09 42.14 28.15 18.15 —
Price performance 12m -0.46 -0.08 0.08 -0.5 0.5 0.55 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 931M 989M 1.11B 1.22B 1.22B 1.15B 1.03B 1.07B
↳ YoY growth +6.2% +12.6% +9.8% -0.3% -5.6% -10.1% +3.9%
↳ 5y CAGR +4.3% +0.9% -0.7%
Borrowings, current (USD) — — 142M 93.5M 26.4M 45.2M 364M 260M 821M 30.8M
Borrowings, non-current (USD) — — 6.78B 5.02B 4.87B 6.98B 5.92B 5.28B 3.23B 3.92B
Lease liabilities (USD) — — — 199M 133M 113M 191M 193M 188M 212M
Cash and deposits (USD) 66M 189M 185M 187M 287M 302M 373M 263M 262M 365M
Intangible assets (USD) — — 4.47B 4.13B 3.96B 5.05B 4.04B 3.68B 3.27B 3.1B
Right-of-use assets (USD) — — — 132M — 108M 119M 121M 157M 165M
Net debt (borrowings + leases - cash) (USD) — — 6.74B 5.13B 4.74B 6.83B 6.11B 5.47B 3.98B 3.79B
Cash flow detail
Operating cash flow (USD) — -168M 201M 354M 930M 954M 844M 870M 841M 624M
Purchases of property, plant and equipment (USD) — -25.2M -37.7M -51.6M -61.6M -111M -133M -146M -149M -129M
Change in receivables (cash effect) (USD) — 14.1M -83.4M -68.9M -102M -112M -45.2M 77M 45.9M 13.6M
Change in inventories (cash effect) (USD) — 19.7M -41.1M -71.1M -69.7M -130M -113M 30.3M -18.5M -109M
Share buybacks (cash effect) (USD) — — — — — — — 0.00 0.00 -75.1M
Interest paid (cash effect) (USD) — -137M -481M -410M -323M -187M -242M -267M -211M -161M
Income taxes paid (cash effect) (USD) — -31.5M -65.6M -112M -42.7M -145M -257M -224M -248M -145M
Share-based compensation (USD) — 48.2M 18.4M 67.9M 44.1M 50.7M 45.8M 40.5M 46.8M 46.4M
Operating cash flow before change in receivables (USD) — -182M 284M 423M 1.03B 1.07B 889M 793M 795M 610M
Free cash flow (OCF - PPE - intangibles) (USD) — -193M 163M 302M 868M 843M 710M 724M 692M 495M
Income detail
Total comprehensive income (USD) — -74.8M -180M 18.4M 224M 508M 629M 352M 597M -363M
Comprehensive income to owners (USD) — -45.4M -180M 18.4M 224M 508M 629M 352M 597M -363M
Reported Feb 14, 2020 Feb 14, 2020 Feb 14, 2020 Feb 14, 2020 Feb 16, 2021 Feb 14, 2023 Feb 14, 2023 Feb 11, 2026 Feb 11, 2026 Feb 11, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

On October 30, 2026, the Compensation and Human Resources Committee (the “Committee”) of the Board of Directors of Avantor, Inc. (the “Company”) approved a special long-term incentive award for the Company’s Executive Vice President, Chief Legal and Compliance Officer and Secretary, Claudius Sokenu, to recognize his overall performance and contributions to the Company, including his leadership in litigation and regulatory management, dispute resolution and corporate governance. The award was granted on October 31, 2026, and is a grant of 62,305 restricted stock units (“RSUs”) under the Company’s 2019 Equity Incentive Plan (the “Plan”). The RSUs will vest in equal installments on the first three anniversaries of the grant date, subject to Mr. Sokenu’s continued employment with the Company through each applicable vesting date.

Avantor® Reports Third Quarter 2026 Results Bull 5 Bear 0 Results

October 28, 2026

  • Download (opens in new window)

  • Net sales of $1,698.3 million; increase of 4.6%; organic increase of 5.2%

  • Diluted GAAP EPS of $0.30; adjusted EPS of $0.22

  • Raised FY 2026 organic revenue growth, adjusted EPS and free cash flow guidance

RADNOR, Pa., Oct. 28, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, reports results that exceeded management's expectations for revenue and adjusted EPS for the third fiscal quarter of 2026.

Avantor. Setting science in motion to create a better world.

Emmanuel Ligner, President and Chief Executive Officer, says: "We are delighted to return to year-over-year growth in the third quarter. We are not done with our Revival journey yet, but this achievement reflects the dedication of our associates and the progress we are making to sharpen our strategic focus and improve execution. Third quarter results exceeded our expectations across revenue and adjusted EPS, and we generated robust free cash flow that allowed us to further strengthen our balance sheet.

"VWR Distribution & Services delivered another quarter of improving revenue performance, with organic growth accelerating to 5.8%, and Bioscience & Medtech Products returned to organic growth as expected. We believe that improving execution and stronger end markets provide a foundation for sustained revenue growth, and we remain focused on execution to build on our positive momentum," Ligner concludes.

Third Quarter 2026

For the three months ended September 30, 2026, net sales were $1,698.3 million, which was up 4.6% compared to the third quarter of 2025. Foreign currency translation had a negative impact of 0.6%, resulting in a 5.2% increase in net sales on an organic basis.

Net income increased to $203.4 million from a net loss of $711.8 million in the third quarter of 2025, and net income margin was 12.0%; adjusted net income was $146.4 million compared to $151.1 million in the prior-year period. Adjusted EBITDA was $256.9 million, with an adjusted EBITDA margin of 15.1%.

Operating income was $139.5 million, with an operating income margin of 8.2%; adjusted operating income was $227.6 million, with an adjusted operating income margin of 13.4%.

Diluted earnings per share on a GAAP basis was $0.30, and adjusted diluted earnings per share was $0.22.

Third Quarter 2026 – Segment Results

VWR Distribution & Services

  • Net sales were $1,233.8 million, a reported increase of 5.0%, as compared to $1,175.0 million in the third quarter of 2025. Foreign currency translation had a negative impact of 0.8%, resulting in a sales increase of 5.8% on an organic basis.
  • Adjusted Operating Income was $119.4 million as compared to $132.0 million in the comparable prior period. Adjusted Operating Income margin was 9.7%. Adjusted Operating Income margin declined versus the prior year due to unfavorable product mix and higher SG&A expenses, partially offset by higher sales volume.

Bioscience & Medtech Products

  • Net sales were $464.5 million, a reported increase of 3.5%, as compared to $448.8 million in the third quarter of 2025. Foreign currency translation had a negative impact of 0.1%, resulting in a 3.6% sales increase on an organic basis.
  • Adjusted Operating Income was $123.4 million, as compared to $119.3 million in the comparable prior period. Adjusted Operating Income margin was 26.6%. Adjusted Operating Income margin was flat versus the prior year due to higher sales volume and commercial excellence, partially offset by higher SG&A expenses.

Adjusted Operating Income is Avantor's segment reporting profitability measure under generally accepted accounting principles and is used by management to measure and evaluate the performance of our Company's business segments.

Balance Sheet and Cash Flow

As of September 30, 2026, total debt, gross, was $3,699.7 million and cash and cash equivalents were $464.3 million.

GAAP net leverage was 9.6x, and adjusted net leverage was 3.1x, as of September 30, 2026.

For the three months ended September 30, 2026, operating cash flow was $195.1 million, while free cash flow was $156.2 million.

Updated 2026 Guidance

Avantor updates its fiscal 2026 financial guidance.

Fiscal 2026 guidance(as of July 29, 2026) Updated Fiscal 2026 guidance(as of October 28, 2026)
Organic revenue growth (1) -0.5% to +0.5% +0.75% to +1.25%
Adjusted EBITDA margin (1) 14.8% to 15.3% 14.8% to 15.3%
Adjusted EPS (1) $0.80 to $0.83 $0.81 to $0.83
Free cash flow (1)(2) $500M to $550M $525M to $550M

(1) Non-GAAP measure (definitions and/or reconciliations below). We are unable to provide a reconciliation of the non-GAAP measures provided in our full-year 2026 guidance without unreasonable effort because of the difficulty in forecasting and quantifying certain amounts and adjustment items with a reasonable degree of certainty including net income, restructuring charges, foreign currency exchange gains and losses and income tax expense. These amounts are dependent upon future events and may be outside of our control. We note that these items could have a significant impact on our full-year results determined in accordance with GAAP.

(2) Excludes cash restructuring costs.

Fiscal 2026 Assumptions

  • Reported revenue growth range is +1.5% to +2.0%, reflecting +0.75% foreign exchange tailwind
  • Blended EUR/USD exchange rate of 1.15
  • Net interest expense is expected to decline modestly when compared to Fiscal 2025
  • Adjusted effective tax rate between 22.0% and 22.5%
  • Fully diluted share count of 679M shares

Conference Call

We will host a conference call to discuss our results today, October 28, 2026 at 8:00 a.m. Eastern Time. The live webcast and presentation, as well as a replay, will be available on the investor section of Avantor's website . 

About Avantor

Avantor is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit corporate.avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.

Use of Non-GAAP Financial Measures

To evaluate our performance, we monitor a number of key indicators. As appropriate, we supplement our results of operations determined in accordance with U.S. generally accepted accounting principles ("GAAP") with certain non-GAAP financial measures that we believe are useful to investors, creditors and others in assessing our performance. These measures should not be considered in isolation or as a substitute for reported GAAP results because they may include or exclude certain items as compared to similar GAAP-based measures, and such measures may not be comparable to similarly titled measures reported by other companies. Rather, these measures should be considered as an additional way of viewing aspects of our operations that provide a more complete understanding of our business. We strongly encourage investors to review our consolidated financial statements included in reports filed with the SEC in their entirety and not rely solely on any one single financial measure or communication.

The non-GAAP financial measures used in this press release are sales growth (decline) on an organic basis, Adjusted Operating Income, Adjusted Operating Income margin, Adjusted EBITDA, Adjusted EBITDA margin, adjusted net income, adjusted EPS, adjusted net leverage, free cash flow and free cash flow conversion.

  • Organic net sales growth (decline) eliminates from our reported net sales change the impacts of revenues from acquisitions and divestitures that occurred in the last year (as applicable) and changes in foreign currency exchange rates. We believe that this measurement is useful to investors as a way to measure and evaluate our underlying commercial operating performance consistently across our segments and the periods presented. This measure is used by our management for the same reason.
  • Adjusted Operating Income is our operating income or loss adjusted for the following items: (i) amortization of acquired intangible assets, (ii) charges associated with the impairment of certain assets, (iii) gain or loss on sale of business, and (iv) certain other adjustments. Adjusted Operating Income margin is Adjusted Operating Income divided by net sales as determined under GAAP. We believe that these measures are useful to investors as ways to analyze the underlying trends in our business consistently across the periods presented. These measures are used by our management for the same reason. Additionally, Adjusted Operating Income is our segment reporting profitability measure under GAAP.
  • Adjusted EBITDA is our net income or loss adjusted for the following items: (i) interest expense, (ii) income tax expense, (iii) amortization of acquired intangible assets, (iv) depreciation expense, (v) losses on extinguishment of debt, (vi) charges associated with the impairment of certain assets, (vii) gain or loss on sale of business, and (viii) certain other adjustments. Adjusted EBITDA margin is Adjusted EBITDA divided by net sales as determined under GAAP. We believe that these measures are useful to investors as ways to analyze the underlying trends in our business consistently across the periods presented. These measures are used by our management for the same reason.
  • Adjusted net income is our net income or loss first adjusted for the following items: (i) amortization of acquired intangible assets, (ii) losses on extinguishment of debt, (iii) charges associated with the impairment of certain assets, (iv) gain or loss on sale of business, and (v) certain other adjustments. From this amount, we then add or subtract an assumed incremental income tax impact on the above-noted pre-tax adjustments, using estimated tax rates, to arrive at Adjusted Net Income. We believe that this measure is useful to investors as a way to analyze the business consistently across the periods presented. This measure is used by our management for the same reason.
  • Adjusted EPS is our adjusted net income divided by our diluted GAAP weighted average share count adjusted for anti-dilutive instruments. We believe that this measure is useful to investors as an additional way to analyze the underlying trends in our business consistently across the periods presented. This measure is used by our management for the same reason.
  • Adjusted net leverage is equal to our gross debt, reduced by our cash and cash equivalents, divided by our trailing 12-month Adjusted EBITDA (excluding stock-based compensation expense and including the expected run-rate effect of cost synergies and the incremental results of completed acquisitions and divestitures as if those acquisitions and divestitures had occurred on the first day of the trailing 12-month period). We believe that this measure is useful to investors as a way to evaluate and measure the Company's capital allocation strategies and the underlying trends in the business. This measure is used by our management for the same reason.
  • Free cash flow is equal to our cash flows from operating activities, less capital expenditures, plus direct transaction costs and income taxes paid related to acquisitions and divestitures (as applicable) in the period. Free cash flow conversion is free cash flow divided by adjusted net income. We believe that these measures are useful to investors as they provide a view on the Company's ability to generate cash for use in financing or investing activities. These measures are used by our management for the same reason.

Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this release.

Forward-Looking and Cautionary Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. These statements may be preceded by, followed by or include the words "aim," "anticipate," "assumption," "believe," "continue," "estimate," "expect," "forecast," "goal," "guidance," "intend," "likely," "long-term," "near-term," "objective," "opportunity," "outlook," "plan," "potential," "project," "projection," "prospects," "seek," "target," "trend," "can," "could," "may," "should," "would," "will," the negatives thereof and other words and terms of similar meaning.

Forward-looking statements are inherently subject to risks, uncertainties and assumptions; they are not guarantees of performance. You should not place undue reliance on these statements. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. Factors that could contribute to these risks, uncertainties and assumptions include, but are not limited to, the factors described in "Risk Factors" in our most recent Annual Report on Form 10-K, and subsequent quarterly reports on Form 10-Q, as such risk factors may be updated from time to time in our periodic filings with the SEC.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. In addition, all forward-looking statements speak only as of the date of this press release. We undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise other than as required under the federal securities laws.

Investor Relations Contact

Chris Fidyk
Vice President, Investor Relations
Avantor 
[email protected]

Global Media Contact

Valerie Collado
Director, External Communications and Community Impact
Avantor
484-885-9338
[email protected]

Avantor, Inc. and subsidiariesUnaudited condensed consolidated statements of operations
(in millions, except per share data) Three months endedSeptember 30, Nine months endedSeptember 30,
2026 2025 2026 2025
Net sales $   1,698.3 $   1,623.8 $   4,972.0 $   4,888.6
Cost of sales 1,163.5 1,097.3 3,399.5 3,273.1
Gross profit 534.8 526.5 1,572.5 1,615.5
Selling, general and administrative expenses 395.3 390.3 1,211.7 1,203.1
Impairment charges — 785.0 — 785.0
Operating income (loss) 139.5 (648.8) 360.8 (372.6)
Interest expense, net (39.9) (44.2) (122.2) (129.8)
Loss on extinguishment of debt (0.8) (0.2) (2.0) (0.2)
Other (expense) income, net (0.8) 3.7 (1.9) (19.5)
Income (loss) before income taxes 98.0 (689.5) 234.7 (522.1)
Income tax benefit (expense) 105.4 (22.3) 50.1 (60.5)
Net income (loss) $      203.4 $    (711.8) $      284.8 $    (582.6)
Earnings (loss) per share:
Basic $       0.30 $      (1.04) $       0.42 $      (0.86)
Diluted $       0.30 $      (1.04) $       0.42 $      (0.86)
Weighted average shares outstanding:
Basic 677.1 681.7 676.3 681.4
Diluted 680.9 681.7 677.7 681.4
Avantor, Inc. and subsidiariesUnaudited condensed consolidated balance sheets
(in millions) September 30, 2026 December 31, 2025
Assets
Current assets:
Cash and cash equivalents $                  464.3 $                  365.4
Accounts receivable, net 1,122.9 1,074.6
Inventory 854.8 818.2
Other current assets 150.6 193.0
Total current assets 2,592.6 2,451.2
Property, plant and equipment, net 778.9 766.8
Other intangible assets, net 2,932.3 3,193.8
Goodwill, net 4,925.9 4,986.9
Other assets 400.3 396.0
Total assets $             11,630.0 $             11,794.7
Liabilities and stockholders' equity
Current liabilities:
Current portion of debt $                   35.0 $                   30.8
Accounts payable 735.4 741.7
Employee-related liabilities 174.0 162.7
Accrued interest 31.5 47.3
Other current liabilities 393.1 396.4
Total current liabilities 1,369.0 1,378.9
Debt, net of current portion 3,648.8 3,915.5
Deferred income tax liabilities 401.9 557.1
Other liabilities 374.4 378.2
Total liabilities 5,794.1 6,229.7
Stockholders' equity:
Common stock including paid-in capital 4,030.5 3,984.8
Treasury stock at cost (75.7) (75.7)
Accumulated earnings 1,957.6 1,672.8
Accumulated other comprehensive loss (76.5) (16.9)
Total stockholders' equity 5,835.9 5,565.0
Total liabilities and stockholders' equity $             11,630.0 $             11,794.7
Avantor, Inc. and subsidiariesUnaudited condensed consolidated statements of cash flows
(in millions) Three months endedSeptember 30, Nine months endedSeptember 30,
2026 2025 2026 2025
Cash flows from operating activities:
Net income (loss) $    203.4 $   (711.8) $    284.8 $   (582.6)
Reconciling adjustments:
Depreciation and amortization 105.3 104.5 315.9 306.9
Impairment charges — 785.0 — 785.0
Stock-based compensation expense 12.5 7.2 36.5 35.1
Non-cash restructuring charges — — 5.0 —
Provision for accounts receivable and   inventory 19.0 16.5 46.2 43.4
Deferred income tax benefit (147.2) (11.9) (141.1) (41.9)
Amortization of deferred financing costs 1.8 2.1 5.3 6.6
Loss on extinguishment of debt 0.8 0.2 2.0 0.2
Foreign currency remeasurement loss (gain) 0.4 (3.1) (0.5) 0.7
Pension termination charges — — — 18.1
Changes in assets and liabilities:
Accounts receivable 12.4 66.2 (68.3) 10.5
Inventory (44.1) (33.4) (90.8) (66.7)
Accounts payable (10.2) (23.5) 7.5 (4.4)
Accrued interest (14.7) (14.8) (15.8) (13.4)
Other assets and liabilities 54.6 25.5 42.9 (27.4)
Other 1.1 (1.3) 2.4 1.0
Net cash provided by operating activities 195.1 207.4 432.0 471.1
Cash flows from investing activities:
Capital expenditures (38.9) (35.7) (110.0) (93.3)
Other 0.4 2.4 1.5 2.5
Net cash used in investing activities (38.5) (33.3) (108.5) (90.8)
Cash flows from financing activities:
Debt borrowings 54.0 67.7 54.0 67.7
Debt repayments (63.1) (439.2) (280.6) (477.3)
Proceeds received from exercise of stock options 12.7 2.3 14.6 4.9
Shares repurchased to satisfy employee tax   obligations for vested stock-based awards (1.1) (0.4) (5.0) (5.4)
Other (0.7) — (0.8) —
Net cash provided by (used in) financing   activities 1.8 (369.6) (217.8) (410.1)
Effect of currency rate changes on cash and cash   equivalents (0.9) (2.0) (6.8) 19.8
Net change in cash, cash equivalents and restricted   cash 157.5 (197.5) 98.9 (10.0)
Cash, cash equivalents and restricted cash, beginning   of period 309.7 452.2 368.3 264.7
Cash, cash equivalents and restricted cash, end of   period $    467.2 $    254.7 $    467.2 $    254.7
Avantor, Inc. and subsidiariesReconciliations of non-GAAP measures
Adjusted EBITDA and Adjusted EBITDA Margin
(dollars in millions, %   based on net sales) Three months ended September 30, Nine months ended September 30,
2026 2025 2026 2025
$ % $ % $ % $ %
Net income (loss) $ 203.4 12.0 % $  (711.8) (43.8) % $ 284.8 5.7 % $  (582.6) (11.9) %
Amortization 75.5 4.4 % 76.1 4.7 % 227.1 4.6 % 225.5 4.6 %
Loss on extinguishment   of debt 0.8 — % 0.2 — % 2.0 — % 0.2 — %
Restructuring, severance,   and related   impairment charges1 8.1 0.5 % 2.2 0.1 % 47.2 0.9 % 28.0 0.6 %
Transformation   expenses2 — — % 13.7 0.8 % — — % 49.5 1.0 %
Reserve for certain legal   matters, net3 1.3 0.1 % 1.6 0.1 % 4.7 0.1 % 5.2 0.1 %
Other4 3.5 0.2 % 7.8 0.5 % 3.9 0.1 % 18.5 0.4 %
Pension termination   charges5 — — % (1.8) (0.1) % — — % 16.3 0.3 %
Impairment charges6 — — % 785.0 48.3 % — — % 785.0 16.1 %
Income tax benefit   applicable to pretax   adjustments (146.2) (8.6) % (21.9) (1.3) % (166.0) (3.3) % (78.0) (1.6) %
Adjusted net income 146.4 8.6 % 151.1 9.3 % 403.7 8.1 % 467.6 9.6 %
Interest expense, net 39.9 2.4 % 44.2 2.7 % 122.2 2.6 % 129.8 2.7 %
Depreciation 29.8 1.7 % 28.4 1.8 % 88.8 1.7 % 81.4 1.7 %
Income tax provision   applicable to   Adjusted net income 40.8 2.4 % 44.2 2.7 % 115.9 2.3 % 138.5 2.7 %
Adjusted EBITDA $ 256.9 15.1 % $ 267.9 16.5 % $ 730.6 14.7 % $ 817.3 16.7 %
____________________
1. Reflects charges incurred during the period related to restructuring initiatives to increase profitability and productivity. Costs included in this caption consist of employee severance, site-exit and contract termination costs, and non-cash impairment charges on long-lived assets associated with site exits.
2. Represents incremental expenses directly associated with the Company's former cost transformation initiative, which concluded in 2025. These expenses are primarily related to the cost of external advisors.
3. Represents charges and legal costs, net of recoveries, incurred in connection with certain litigation and other contingencies that management evaluates separately from core operating performance.
4. Represents net foreign currency (gain) loss from financing activities, other stock-based compensation expense (benefit) and certain other items that management evaluates separately from core operating performance. The 2025 periods also include a purchase price adjustment related to the 2024 sale of our Clinical Services business and $6.1 million of severance and transition costs associated with the replacement of our Chief Executive Officer.
5. Represents pension termination charges related to termination of our U.S. Pension Plan.
6. Represents the $785.0 million non-cash goodwill impairment charge recognized in the third quarter of 2025 related to the former Distribution reporting unit.
Avantor, Inc. and subsidiaries Reconciliations of non-GAAP measures (continued)
Adjusted Operating Income and Adjusted Operating Income Margin
(dollars in millions, %   based on net sales) Three months ended September 30, Nine months ended September 30,
2026 2025 2026 2025
$ % $ % $ % $ %
Net income (loss) $ 203.4 12.0 % $  (711.8) (43.8) % $ 284.8 5.7 % $  (582.6) (11.9) %
Interest expense, net 39.9 2.4 % 44.2 2.7 % 122.2 2.6 % 129.8 2.7 %
Income tax (benefit)   expense (105.4) (6.2) % 22.3 1.4 % (50.1) (1.0) % 60.5 1.1 %
Loss on extinguishment   of debt 0.8 — % 0.2 — % 2.0 — % 0.2 — %
Other (expense)   income, net 0.8 — % (3.7) (0.3) % 1.9 — % 19.5 0.5 %
Operating income   (loss) 139.5 8.2 % (648.8) (40.0) % 360.8 7.3 % (372.6) (7.6) %
Amortization 75.5 4.4 % 76.1 4.7 % 227.1 4.6 % 225.5 4.6 %
Restructuring,   severance, and   related impairment   charges1 8.1 0.5 % 2.2 0.1 % 47.2 0.9 % 28.0 0.6 %
Transformation   expenses2 — — % 13.7 0.8 % — — % 49.5 1.0 %
Reserve for certain legal   matters, net3 1.3 0.1 % 1.6 0.1 % 4.7 0.1 % 5.2 0.1 %
Other4 3.2 0.2 % 7.5 0.6 % 3.5 — % 11.7 0.2 %
Impairment charges5 — — % 785.0 48.3 % — — % 785.0 16.1 %
Adjusted Operating   Income $ 227.6 13.4 % $ 237.3 14.6 % $ 643.3 12.9 % $ 732.3 15.0 %
____________________
1. Reflects charges incurred during the period related to restructuring initiatives to increase profitability and productivity. Costs included in this caption consist of employee severance, site-exit and contract termination costs, and non-cash impairment charges on long-lived assets associated with site exits.
2. Represents incremental expenses directly associated with the Company's former cost transformation initiative, which concluded in 2025. These expenses are primarily related to the cost of external advisors.
3. Represents charges and legal costs, net of recoveries, incurred in connection with certain litigation and other contingencies that management evaluates separately from core operating performance.
4. Represents other stock-based compensation expense (benefit) and certain other items that management evaluates separately from core operating performance. The 2025 periods also include a purchase price adjustment related to the 2024 sale of our Clinical Services business and $6.1 million of severance and transition costs associated with the replacement of our Chief Executive Officer.
5. Represents the $785.0 million non-cash goodwill impairment charge recognized in the third quarter of 2025 related to the former Distribution reporting unit.
Avantor, Inc. and subsidiariesReconciliations of non-GAAP measures (continued)
Adjusted earnings per share
(shares in millions) Three months endedSeptember 30, Nine months endedSeptember 30,
2026 2025 2026 2025
Diluted earnings (loss) per share (GAAP) $      0.30 $     (1.04) $      0.42 $     (0.86)
Amortization 0.11 0.11 0.34 0.33
Loss on extinguishment of debt — — — —
Restructuring, severance, and related impairment   charges 0.01 — 0.07 0.04
Transformation expenses — 0.02 — 0.07
Reserve for certain legal matters, net — — 0.01 0.01
Other 0.01 0.01 — 0.04
Pension termination charges — — — 0.02
Impairment charges — 1.15 — 1.15
Income tax benefit applicable to pretax adjustments (0.21) (0.03) (0.24) (0.11)
Adjusted EPS (non-GAAP) $      0.22 $      0.22 $      0.60 $      0.69
Weighted average diluted shares outstanding:
Share count for Adjusted EPS (non-GAAP) 680.9 681.7 677.7 681.4
Free cash flow
(in millions) Three months endedSeptember 30, Nine months endedSeptember 30,
2026 2025 2026 2025
Net cash provided by operating activities $    195.1 $    207.4 $    432.0 $    471.1
Capital expenditures (38.9) (35.7) (110.0) (93.3)
Divestiture-related transaction expenses and taxes   paid — — 2.2 1.4
Free cash flow (non-GAAP) $    156.2 $    171.7 $    324.2 $    379.2
GAAP net leverage
(dollars in millions) September 30,2026
Total debt, gross $      3,699.7
Less cash and cash equivalents (464.3)
$      3,235.4
Trailing twelve months net income $         337.2
GAAP net leverage 9.6 x
Adjusted net leverage
(dollars in millions) September 30,2026
Total debt, gross $      3,699.7
Less cash and cash equivalents (464.3)
$      3,235.4
Trailing twelve months Adjusted EBITDA $         982.7
Trailing twelve months ongoing stock-based compensation expense 47.5
$      1,030.2
Adjusted net leverage (non-GAAP) 3.1 x
Avantor, Inc. and subsidiaries Reconciliations of non-GAAP measures (continued)
Net sales by segment
(in millions) September 30, Reconciliation of net sales growth(decline) to organic net sales growth(decline)
Net salesgrowth(decline) Foreigncurrencyimpact Organicnet salesgrowth(decline)
2026 2025
$ $ $ $ $
Three months ended:
Bioscience & Medtech Products $      464.5 $      448.8 $       15.7 $       (0.6) $       16.3
VWR Distribution & Services 1,233.8 1,175.0 58.8 (9.0) 67.8
Total $   1,698.3 $   1,623.8 $       74.5 $       (9.6) $       84.1
Nine months ended:
Bioscience & Medtech Products $   1,347.7 $   1,351.1 $       (3.4) $       15.7 $      (19.1)
VWR Distribution & Services 3,624.3 3,537.5 86.8 54.7 32.1
Total $   4,972.0 $   4,888.6 $       83.4 $       70.4 $       13.0
(dollars in millions, % based on net sales) September 30, Reconciliation of net sales growth(decline) to organic net sales growth(decline)
Net salesgrowth(decline) Foreigncurrencyimpact Organicnet salesgrowth(decline)
2026 2025
$ $ % % %
Three months ended:
Bioscience & Medtech Products $     464.5 $     448.8 3.5 % (0.1) % 3.6 %
VWR Distribution & Services 1,233.8 1,175.0 5.0 % (0.8) % 5.8 %
Total $   1,698.3 $   1,623.8 4.6 % (0.6) % 5.2 %
Nine months ended:
Bioscience & Medtech Products $   1,347.7 $   1,351.1 (0.3) % 1.1 % (1.4) %
VWR Distribution & Services 3,624.3 3,537.5 2.5 % 1.6 % 0.9 %
Total $   4,972.0 $   4,888.6 1.7 % 1.4 % 0.3 %
Adjusted Operating Income by segment
(dollars in millions, %represent AdjustedOperating Income margin) Three months ended September 30, Nine months ended September 30,
2026 2025 2026 2025
$ % $ % $ % $ %
Bioscience & MedtechProducts $ 123.4 26.6 % $ 119.3 26.6 % $ 343.7 25.5 % $ 365.2 27.0 %
VWR Distribution &Services 119.4 9.7 % 132.0 11.2 % 351.2 9.7 % 421.5 11.9 %
Corporate (15.2) — % (14.0) — % (51.6) — % (54.4) — %
Total $ 227.6 13.4 % $ 237.3 14.6 % $ 643.3 12.9 % $ 732.3 15.0 %

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-reports-third-quarter-2026-results-302921384.html

SOURCE Avantor and Financial News

View All News

Quick Links

Investor Contact

Chris Fidyk
Vice President, Investor Relations
[email protected]

Mailing Address

Radnor Corporate Center
100 Matsonford Road
Bldg 1 Ste 200
P.O. Box 6660,
Radnor, PA 19087

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Avantor, Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Avantor, Inc. to send you the requested Investor Email Alert updates.

* Required

Email Address *

Investor Alert OptionsInvestor Alert Options *

News
Quarterly Reports
Annual Reports
SEC Filings
End of Day Stock Quote
Events & Presentations

Submit Submit

Unsubscribe

Email Alert Sign Up Confirmation

Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit corporate.avantorsciences.com  and find us on LinkedIn , X (Twitter) and Facebook.

Customer Support

Shopping

Global Contact

Ethics Helpline

Work With Avantor

About Avantor

How to Buy

Investors

News

Financials

Stock Information

Careers

Careers Home

Open Roles

Terms and Conditions

Terms of Use

Privacy Policy

Equal Opportunity Statement

Do Not Share My Personal Information

© 2026 Avantor, Inc.
© 2026 FORTUNE Media IP Limited All rights reserved. Used under license.

Avantor appoints new Chief Information Officer Bull 0 Bear 0 Management

October 26, 2026

RADNOR, Pa., Oct. 26, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, welcomes Mikey Santiago as its new Chief Information Officer.

Avantor appoints Mikey Santiago Chief Information Officer.

In this role, Mikey will lead Avantor's global information technology strategy, advancing the company's digital transformation agenda while supporting growth, operational excellence, customer experience, and innovation across the enterprise.

Emmanuel Ligner, President and CEO, Avantor, says: "Mikey brings an exceptional combination of business knowledge, technology leadership, and a proven ability to execute transformation at scale. With Mikey's experience in complex integrations, modernization efforts and AI-driven innovation, he will help position Avantor for the future."

Mikey joins Avantor with more than two decades of technology leadership experience, including serving as a four-time CIO and holding senior leadership roles within the Danaher Corporation and its operating companies. Throughout his career, he has led enterprise-wide digital transformations, major acquisitions and integrations, cloud modernization programs, cybersecurity initiatives, and the deployment of advanced analytics and AI capabilities that have delivered significant business impact.

Mikey Santiago says: "I am excited to join Avantor and contribute to the next chapter of its growth and transformation. By aligning technology, data, and digital capabilities with business strategy, we have an opportunity to create meaningful value for our customers and strengthen our impact on the customers and communities we serve. I look forward to working with talented colleagues across the organization and leading a team committed to innovation, collaboration, and results."

Mikey holds a master of business administration from University of Southern California, completed graduate studies in computer science and cognitive science at University of California, San Diego, and holds bachelor degrees in computer science and mathematics from California State University.

Meet Avantor's full leadership team here .

**About Avantor
**Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com  and find us on LinkedIn , X (Twitter)  and Facebook .

**Investors:
**[email protected]

**Media Inquiries:
**[email protected]

Avantor. Setting science in motion to create a better world.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-appoints-new-chief-information-officer-302918948.html

SOURCE Avantor and Financial News

View All News

Quick Links

Investor Contact

Chris Fidyk
Vice President, Investor Relations
[email protected]

Mailing Address

Radnor Corporate Center
100 Matsonford Road
Bldg 1 Ste 200
P.O. Box 6660,
Radnor, PA 19087

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Avantor, Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Avantor, Inc. to send you the requested Investor Email Alert updates.

* Required

Email Address *

Investor Alert OptionsInvestor Alert Options *

News
Quarterly Reports
Annual Reports
SEC Filings
End of Day Stock Quote
Events & Presentations

Submit Submit

Unsubscribe

Email Alert Sign Up Confirmation

Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit corporate.avantorsciences.com  and find us on LinkedIn , X (Twitter) and Facebook.

Customer Support

Shopping

Global Contact

Ethics Helpline

Work With Avantor

About Avantor

How to Buy

Investors

News

Financials

Stock Information

Careers

Careers Home

Open Roles

Terms and Conditions

Terms of Use

Privacy Policy

Equal Opportunity Statement

Do Not Share My Personal Information

© 2026 Avantor, Inc.
© 2026 FORTUNE Media IP Limited All rights reserved. Used under license.

Prompts

Avantor, Inc. (ticker AVTR), listed in United States.

Company History

Date Change Detail
Feb 8, 2019 Renamed Vail Holdco Corp → AVANTOR, INC.

ETFs Holding Avantor, Inc.

ETF Weight in ETF Shares Market value As of
PINK 3.90% 859,446 $ 13.046M Nov 17, 2026
EPSB 2.00% 9,710 $ 150.893K Nov 13, 2026
LSEQ 0.80% 8,294 $ 128.889K Nov 13, 2026
FPAG 0.65% 355,906 $ 3.523M Jun 30, 2026
DFSV 0.60% 10,631,455 $ 166.063M Nov 12, 2026
BTAL short -0.46% -132,572 $ -1.312M Jun 30, 2026
DFAT 0.29% 5,905,730 $ 92.248M Nov 12, 2026
VFVA 0.22% 145,932 $ 2.122M Aug 31, 2026
JMEE 0.21% 392,618 $ 5.96M Nov 17, 2026
DFAS 0.17% 3,615,484 $ 56.474M Nov 12, 2026
REMC 0.15% 513 $ 5,078.70 Jun 30, 2026
MSSM 0.08% 39,522 $ 574.65K Aug 31, 2026
AVMC 0.08% 27,173 $ 416.29K Nov 16, 2026
FTLS short -0.07% -117,494 $ 0.00 Nov 16, 2026
SMDX 0.06% 4,892 $ 74.945K Nov 17, 2026
DFSU 0.04% 61,289 $ 957.334K Nov 12, 2026
IALT short -0.04% -210,407 $ -3.223M Nov 16, 2026
DFAC 0.02% 1,199,155 $ 18.731M Nov 12, 2026
AVLC 0.02% 20,330 $ 311.456K Nov 16, 2026
DFAU 0.02% 161,839 $ 2.528M Nov 12, 2026
DXUV 0.02% 72,433 $ 1.131M Nov 12, 2026
DFUS 0.01% 204,490 $ 3.194M Nov 12, 2026
VSLU 0.01% 7,447 $ 73.725K Jun 30, 2026
DCOR 0.01% 348,505 $ 5.444M Nov 12, 2026
AVUS 0.01% 64,309 $ 985.214K Nov 16, 2026
AVSU 0.01% 2,226 $ 34.102K Nov 16, 2026
DFUV 0.00% 22,958 $ 358.604K Nov 12, 2026
EBI 0.00% 380 $ 5,525.20 Aug 31, 2026
NTRL short 0.00% -9,296 $ 0.00 Nov 16, 2026